Hepadnavirus Infections and Liver Cancer

嗜肝DNA病毒感染和肝癌

基本信息

  • 批准号:
    7384464
  • 负责人:
  • 金额:
    $ 56.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-06-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The host immune response to chronic HBV infection produces persistent liver injury leading to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), in parallel with partial clearance of the virus from a large fraction of hepatocytes. However, antiviral therapies to completely eliminate the infection are ineffective in 70-90% of carriers. In contrast, transient infections can be rapidly cleared through the action of the immune system in over 90% of adults newly infected with HBV. Ideally, rational approaches for treatment should be via manipulation of the immune system to induce a similar rapid clearance of chronic infections, or the application of antiviral drug therapies that mimic key steps in the antiviral response. However, there is little agreement about the essential components of viral clearance during a transient infection, and almost nothing is known about the basis for partial clearance in chronic infections. The following specific aims will address these issues, using woodchucks transiently and chronically infected with woodchuck hepatitis virus. Specific Aim 1: A major unresolved issue is whether massive cell death is essential during resolution of hepadnavirus infections in order to eliminate viral nucleic acids from the liver. Experiments will be carried out to determine how viral nucleic acids are eliminated from hepatocytes and whether hepatocyte death and compensatory proliferation may play an essential role in this process. Specific Aim 2: We recently obtained evidence of clonal expansion (>1000 cells/clone) of a large fraction of hepatocytes in livers of chronically infected woodchucks, and hypothesize that partial clearance of the virus as well as neoplastic progression may be byproducts of clonal selection of hepatocytes that have lost the ability to support high titer WHV replication. We will test this hypothesis and examine the possibility that this selection might also be used therapeutically to repopulate the liver with virus resistant hepatocytes. In summary, these studies will determine if cell death and compensatory regeneration are essential for virus clearance by the immune system. They will also determine if experimental induction of an antiviral state in a subpopulation of hepatocytes has therapeutic value or, in contrast, may enhance progression to HCC by facilitating outgrowth of virus resistant hepatocytes with oncogenic mutations.
描述(由申请人提供):宿主对慢性 HBV 感染的免疫反应会产生持续性肝损伤,导致纤维化、肝硬化和肝细胞癌 (HCC),同时从大部分肝细胞中部分清除病毒。 然而,完全消除感染的抗病毒疗法对 70-90% 的携带者无效。 相比之下,在 90% 以上的新感染 HBV 的成年人中,短暂性感染可以通过免疫系统的作用迅速清除。 理想情况下,合理的治疗方法应该是通过操纵免疫系统来诱导慢性感染的类似快速清除,或者应用模仿抗病毒反应中关键步骤的抗病毒药物疗法。 然而,对于短暂感染期间病毒清除的基本组成部分几乎没有达成一致,并且对于慢性感染中部分清除的基础几乎一无所知。 以下具体目标将通过使用暂时和慢性感染土拨鼠肝炎病毒的土拨鼠来解决这些问题。 具体目标 1:一个未解决的主要问题是,在解决肝炎病毒感染的过程中,为了消除肝脏中的病毒核酸,大量细胞死亡是否是必需的。将进行实验以确定病毒核酸如何从肝细胞中消除,以及肝细胞死亡和代偿性增殖是否在此过程中发挥重要作用。 具体目标 2:我们最近获得了慢性感染土拨鼠肝脏中大部分肝细胞克隆扩张(>1000 个细胞/克隆)的证据,并假设病毒的部分清除以及肿瘤进展可能是肝细胞克隆选择的副产品,这些肝细胞已经失去了支持高滴度 WHV 复制的能力。 我们将检验这一假设,并检验这种选择也可用于治疗性地用抗病毒肝细胞重新填充肝脏的可能性。 总之,这些研究将确定细胞死亡和代偿性再生是否对于免疫系统清除病毒至关重要。他们还将确定在肝细胞亚群中实验诱导抗病毒状态是否具有治疗价值,或者相​​反,是否可以通过促进具有致癌突变的病毒抗性肝细胞的生长来促进肝癌的进展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Mason其他文献

William Mason的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Mason', 18)}}的其他基金

2007 Molecular Biology of Hepatitis B Viruses Meeting
2007年乙型肝炎病毒分子生物学会议
  • 批准号:
    7333169
  • 财政年份:
    2007
  • 资助金额:
    $ 56.22万
  • 项目类别:
Hepadnavirus Infections and Liver Cancer
嗜肝DNA病毒感染和肝癌
  • 批准号:
    6965836
  • 财政年份:
    2005
  • 资助金额:
    $ 56.22万
  • 项目类别:
Hepadnavirus Infections and Liver Cancer
嗜肝DNA病毒感染和肝癌
  • 批准号:
    7071824
  • 财政年份:
    2005
  • 资助金额:
    $ 56.22万
  • 项目类别:
Hepadnavirus Infections and Liver Cancer
嗜肝DNA病毒感染和肝癌
  • 批准号:
    7187385
  • 财政年份:
    2005
  • 资助金额:
    $ 56.22万
  • 项目类别:
Hepadnavirus Infections and Liver Cancer
嗜肝DNA病毒感染和肝癌
  • 批准号:
    7572963
  • 财政年份:
    2005
  • 资助金额:
    $ 56.22万
  • 项目类别:
PATHOBIOLOGY OF ACUTE AND CHRONIC HEPADNAVIRUS INFECTIONS
急性和慢性肝炎病毒感染的病理学
  • 批准号:
    6569660
  • 财政年份:
    2001
  • 资助金额:
    $ 56.22万
  • 项目类别:
PATHOBIOLOGY OF ACUTE AND CHRONIC HEPADNAVIRUS INFECTIONS
急性和慢性肝炎病毒感染的病理学
  • 批准号:
    6442928
  • 财政年份:
    2001
  • 资助金额:
    $ 56.22万
  • 项目类别:
PATHOBIOLOGY OF ACUTE AND CHRONIC HEPADNAVIRUS INFECTIONS
急性和慢性肝炎病毒感染的病理学
  • 批准号:
    6300250
  • 财政年份:
    2000
  • 资助金额:
    $ 56.22万
  • 项目类别:
PATHOBIOLOGY OF ACUTE AND CHRONIC HEPADNAVIRUS INFECTIONS
急性和慢性肝炎病毒感染的病理学
  • 批准号:
    6347296
  • 财政年份:
    2000
  • 资助金额:
    $ 56.22万
  • 项目类别:
PATHOBIOLOGY OF ACUTE AND CHRONIC HEPADNAVIRUS INFECTIONS
急性和慢性肝炎病毒感染的病理学
  • 批准号:
    6102246
  • 财政年份:
    1999
  • 资助金额:
    $ 56.22万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 56.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了